Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 5, 2010, Pages 970-977

  Hsu, Ching Sheng ^a,b   Liu, Chen Hua ^b,c   Liu, Chun Jen ^b,c   Hsu, Shih Jer ^b,c   Chen, Chi Ling ^b   Hwang, Juey Jen ^c   Lai, Ming Yang ^b,c,d   Chen, Pei Jer ^b,c,d   Chen, Ding Shinn ^b,c   Kao, Jia Horng ^b,c,d  

^a TZU CHI UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d Department of Medical Research ^*  (Canada)

Author keywords

Genotype; Hepatic fibrosis; Hepatitis C virus; Histology; Metabolic profile

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN; RNA; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; DEMOGRAPHY; DIABETES MELLITUS; FATTY LIVER; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RNA EXTRACTION; BODY MASS; CHRONIC HEPATITIS C; DIET RESTRICTION; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; AGE; ANALYSIS; BLOOD; CHI SQUARE DISTRIBUTION; COMPLICATION; CROSS-SECTIONAL STUDY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TAIWAN; VIROLOGY;

ADULT; AGE FACTORS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; CHOLESTEROL; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TAIWAN;

EID: 77951701962     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06186.x     Document Type: Article

References (47)

1. Kao JH, Chen DS. Transmission of hepatitis C virus in Asia: past and present perspectives. J. Gastroenterol. Hepatol. 2000 15 (Suppl. E91 6.
2. Chen DS. Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp. 1995 25 : 27 32.
3. Taliani G, Gemignani G, Ferrari C et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 2006 130 : 1098 1106.
4. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997 349 : 825 832.
5. Leandro G, Mangia A, Hui J et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006 130 : 1636 1642.
6. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004 53 : 451 455.
7. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003 37 : 600 609.
8. Mangia A, Minerva N, Bacca D et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008 47 : 43 50.
9. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004 126 : 586 597.
10. Dharancy S, Malapel M, Perlemuter G et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005 128 : 334 342.
11. O'Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 2007 45 : 895 898.
12. Sud A, Hui JM, Farrell GC et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004 39 : 1239 1247.
13. Chen CL, Yang HI, Yang WS et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008 135 : 111 121.
14. Petta S, Camma C, Marco VD et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am. J. Gastroenterol. 2008 103 : 1136 1144.
15. Sanyal AJ, Contos MJ, Sterling RK et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am. J. Gastroenterol. 2003 98 : 2064 2071.
16. Veldt BJ, Chen W, Heathcote EJ et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008 47 : 1856 1862.
17. Mallat A, Preaux AM, Blazejewski S, Dhumeaux D, Rosenbaum J, Mavier P. Effect of simvastatin, an inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells. Hepatology 1994 20 : 1589 1594.
18. Hickman IJ, Powell EE, Prins JB et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J. Hepatol. 2003 39 : 1042 1048.
19. Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006 113 : 898 918.
20. Reddy KR, Govindarajan S, Marcellin P et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J. Viral Hepat. 2008 15 : 129 136.
21. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006 55 : 123 130.
22. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001 33 : 1358 1364.
23. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005 54 : 1003 1008. (Pubitemid 40873917)
24. Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008 47 : 2127 2133.
25. Sterling RK, Contos MJ, Smith PG et al. Steatohepatitis: risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2008 47 : 1118 1127.
26. Hsu CS, Liu CJ, Liu CH et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int. 2008 28 : 271 277.
27. Gopal K, Johnson TC, Gopal S et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006 44 : 335 340.
28. Moucari R, Asselah T, Cazals-Hatem D et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008 134 : 416 423.
29. Hsu CS, Liu CH, Liu CJ et al. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am. J. Gastroenterol. 2009 104 : 598 604.
30. Bonora E, Targher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000 23 : 57 63.
31. Hsu CS, Liu CH, Liu CJ et al. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir. Ther. 2009 14 : 45 54.
32. Kao JH, Lin HH, Chen PJ et al. Serotyping of hepatitis C virus in chronic type C hepatitis in Taiwan: correlation with genotypes. J. Gastroenterol. 1996 31 : 224 227.
33. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996 24 : 289 293.
34. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999 94 : 2467 2474.
35. Huang KC. Obesity and its related diseases in Taiwan. Obes. Rev. 2008 9 (Suppl. 1 32 4.
36. Mirandola S, Realdon S, Iqbal J et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006 130 : 1661 1669.
37. Miyanari Y, Atsuzawa K, Usuda N et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol. 2007 9 : 1089 1097.
38. Hsu CS, Liu CJ, Liu CH et al. Metabolic profiles in patients with chronic hepatitis C: a case-control study. Hepatol. Int. 2008 2 : 250 257.
39. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ. 2003 10 (Suppl. 1 S59 67.
40. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004 126 : 529 540.
41. Poynard T, Ratziu V, McHutchison J et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003 38 : 75 85. (Pubitemid 36775798)
42. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J. Hepatol. 2008 48 : 721 727.
43. Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008 48 : 723 731.
44. Paradis V, Perlemuter G, Bonvoust F et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001 34 : 738 744.
45. Sugimoto R, Enjoji M, Kohjima M et al. High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase. Liver Int. 2005 25 : 1018 1026.
46. Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 2008 48 : 80 7.
47. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005 42 : 5 13.